Action on diabetic macular oedema: Achieving optimal patient management in treating visual impairment due to diabetic eye disease

Eye (Basingstoke)

Volumn 31, Issue S1, 2017, Pages S1-S20

  Gale, R ^a,b   Scanlon, P H ^a,c   Evans, M ^a,d   Ghanchi, F ^a,e   Yang, Y ^a,f   Silvestri, G ^a,g   Freeman, M ^a,h   Maisey, A ^a,i   Napier, J ^a,j  

^a Action on DMO Group   (United Kingdom)

^b YORK HOSPITAL   (United Kingdom)

^c GLOUCESTERSHIRE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d LLANDOUGH HOSPITAL   (United Kingdom)

^e BRADFORD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^g ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^h ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^j Bayer plc UK   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; BLINDNESS; CLINICAL AUDIT; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DYSLIPIDEMIA; EARLY INTERVENTION; GLOBAL HEALTH; GLYCEMIC CONTROL; HEALTH CARE PERSONNEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; NURSE; NURSING ROLE; OPHTHALMOLOGIST; PATIENT CARE; PATIENT COMPLIANCE; PATIENT REFERRAL; PERSONAL EXPERIENCE; PREVALENCE; SCREENING; TEXT MESSAGING; UNITED KINGDOM; DISEASE MANAGEMENT; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; LASER COAGULATION; MACULAR EDEMA; METABOLISM; NURSE SPECIALIST; PRACTICE GUIDELINE; VISION DISORDERS; VISUAL SYSTEM EXAMINATION; VISUALLY IMPAIRED PERSON; VITRECTOMY;

ANGIOGENESIS INHIBITORS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; DISEASE MANAGEMENT; GLUCOCORTICOIDS; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LASER COAGULATION; MACULAR EDEMA; NURSE SPECIALISTS; PATIENT-CENTERED CARE; PREVALENCE; UNITED KINGDOM; VISION DISORDERS; VISUALLY IMPAIRED PERSONS; VITRECTOMY;

EID: 85044561612     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2017.53     Document Type: Article

References (83)

1. World Health Organization. Global Report on Diabetes. World Health Organization: Geneva, Switzerland, 2016. Available at: apps.who.int/iris/bitstream/10665/204871/1/9789241565257-eng.pdf.
2. International Diabetes Federation. IDF Diabetes, 7 ed. International Diabetes Federation: Brussels, Belgium, 2015 Available at: http://www.diabetesatlas.org.
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387(10027): 1513-1530.
4. Diabetes UK. Available at: https://www.diabetes.org.uk/Professionals/Position-statements-reports/Statistics/Diabetes-prevalence-2016/.
5. Public Health England (PHE). Diabetes Prevalence Model. Public Health England: London, UK, 2016.
6. Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open 2016; 6(1): e010210.
7. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009; 338: b880.
8. Hamer M, Kengne AP, Batty GD, Cooke D, Stamatakis E. Temporal trends in diabetes prevalence and key diabetes risk factors in Scotland, 2003-2008. Diabet Med 2011; 28(5): 595-598.
9. Imkampe AK, Gulliford MC. Increasing socio-economic inequality in type 2 diabetes prevalence-repeated cross-sectional surveys in England 1994-2006. Eur J Public Health 2011; 21(4): 484-490.
10. Health and Social Care Information Centre. National Diabetes Audit 2013-14 and 2014-15. Report 1: Care Processes and Treatment Targets. Published 28 January 2016 by the Health and Social Care Information Centre (HSCIC). Available at: http://content.digital.nhs.uk/catalogue/PUB19900/nati-diab-rep1-audi-2013-15.pdf.
11. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(9995): 743-800.
12. Health and Social Care Information Centre. National Diabetes Audit 2012-13 Report 2: Complications and mortality. Published in 2015 by the Health and Social Care Information Centre (HSCIC). Available at: http://content.digital.nhs.uk/catalogue/PUB16496/nati-diab-audi-12-13-rep2.pdf.
13. McEwan P, Larsen Thorsted B, Wolden M, Jacobsen J, Evans M. Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England. BMJ Open Diabetes Res Care 2015; 3(1): e000057.
14. Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE. Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherence 2016; 10: 1573-1581.
15. Strain WD, Cos X, Hirst M, Vencio S, Mohan V, Vokó Z et al. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pract 2014; 105(3): 302-312.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-986.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-853.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-1589.
19. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58(3): 429-442.
20. Aiello LPDCCT/EDIC Research Group. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37(1): 17-23.
21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703-713.
22. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348(5): 383-393.
23. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358(6): 580-591.
24. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (NG28). NICE guideline, December 2015. Available at: https://www.nice.org.uk/guidance/ng28.
25. Evans M, Peter R. Blood glucose lowering therapies. In: Stehouwer CDA, Schaper N (eds). Therapeutic Strategies in Diabetes. Clinical Publishing: Oxford, UK, 2009; 3-25.
26. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012; 29(5): 682-689.
27. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008; 10(Suppl 1): 25-32.
28. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 347: f4533.
29. Driver and Vehicle Licensing Agency (DVLA). Diabetes mellitus: assessing fitnesss to drive. Available at: https://www.gov.uk/guidance/diabetes-mellitus-assessing-fitness-to-drive.
30. Driver and Vehicle Licensing Agency (DVLA). Hypoglycaemia and driving. Available at: https://www.gov.uk/hypoglycaemia-and-driving.
31. Brod M, Wolden M, Christensen T, Bushnell DM. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab 2013; 15(6): 546-557.
32. Little SA, Leelarathna L, Barendse SM, Walkinshaw E, Tan HK, Lubina Solomon A et al. Severe hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention. Diabetes Metab Res Rev 2014; 30(3): 175-190.
33. Bruderer SG, Bodmer M, Jick SS, Bader G, Schlienger RG, Meier CR. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK-a nested case-control analysis. Diabetes Obes Metab 2014; 16(9): 801-811.
34. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 2012; 35(6): 1279-1284.
35. Winkley K, Evwierhoma C, Amiel SA, Lempp HK, Ismail K, Forbes A. Patient explanations for non-attendance at structured diabetes education sessions for newly diagnosed Type 2 diabetes: a qualitative study. Diabet Med 2015; 32(1): 120-128.
36. Shubrook JH Jr. Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. J Am Osteopath Assoc 2014; 114(5 Suppl 2): S6-13.
37. Scanlon PH, Aldington SJ, Stratton IM. Delay in diabetic retinopathy screening increases the rate of detection of referable diabetic retinopathy. Diabet Med 2014; 31(4): 439-442.
38. Public Health England. Pathway Standards for NHS Diabetic Eye Screening Programme. Public Health England: London, UK, 2016.
39. Zoega GM, Gunnarsdóttir T, Björnsdóttir S, Hreietharsson AB, Viggósson G, Stefánsson E. Screening compliance and visual outcome in diabetes. Acta Ophthalmol Scand 2005; 83(6): 687-690.
40. Scanlon PH, Stratton IM, Leese GP, Bachmann MO, Land M, Jones C et al. Screening attendance, age group and diabetic retinopathy level at first screen. Diabet Med 2016; 33(7): 904-911.
41. Department of Health. Public health functions to be exercised by NHS England. Service Specification No.22. NHS Diabetic Eye Screening Programme. Government of UK: NHS England: UK, 2013.
42. Scanlon PH, Malhotra R, Thomas G, Foy C, Kirkpatrick JN, Lewis-Barned N et al. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. Diabet Med 2003; 20(6): 467-474.
43. Scanlon PH, Malhotra R, Greenwood RH, Aldington SJ, Foy C, Flatman M et al. Comparison of two reference standards in validating two field mydriatic digital photography as a method of screening for diabetic retinopathy. Br J Ophthalmol 2003; 87(10): 1258-1263.
44. NHS Scotland. Scottish Diabetic Retinopathy Screening Collaborative Annual Report 2014-2015.
45. Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open 2014; 4(2): e004015.
46. Keenan TD, Johnston RL, Donachie PH, Sparrow JM, Stratton IM, Scanlon P. United Kingdom National Ophthalmology Database Study: Diabetic Retinopathy; Report 1: prevalence of centre-involving diabetic macular oedema and other grades of maculopathy and retinopathy in hospital eye services. Eye (Lond) 2013; 27(12): 1397-1404.
47. Scanlon PH. Why do patients still require surgery for the late complications of proliferative diabetic retinopathy? Eye (Lond) 2010; 24(3): 435-440.
48. Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S et al. Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia 2014; 57(12): 2465-2474.
49. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008; 115(11): 1859-1868.
50. Scanlon PH, Stratton IM, Histed M, Chave SJ, Aldington SJ. The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. Acta Ophthalmol 2013; 91(5): e335-e339.
51. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991; 98(5 Suppl): 823-833.
52. Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess 2015; 19(74): 1-116.
53. Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sight threatening diabetic retinopathy. Diabetes Care 2013; 36(3): 580-585.
54. Taylor-Phillips S, Mistry H, Leslie R, Todkill D, Tsertsvadze A, Connock M et al. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review. Br J Ophthalmol 2016; 100(1): 105-114.
55. Mackenzie S, Schmermer C, Charnley A, Sim D, Tah Vikas, Dumskyj M et al. SDOCT imaging to identify macular pathology in patients diagnosed with diabetic maculopathy by a digital photographic retinal screening programme. PLoS One 2011; 6(5): e14811.
56. Egan C, Rudisill C, Owen A, Rudnicka A, Sadda S, Taylor P et al. Automated diabetic retinopathy image assessment softwares: diagnostic accuracy and cost-effectiveness compared to human graders. Free paper presented at the 16th European Society of Retina Specialists (EURETINA) Congress; Copenhagen, Denmark, 8-11 September 2016.
57. Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010; 26(7): 1587-1597.
58. Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol 2012; 96(3): 345-349.
59. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open 2013; 3(3): e002269.
60. National Institute for Health and Care Excellence. Dexamethasone intravitreal implant for treating diabetic macular oedema (July 2015). NICE technology appraisal guidance TA349.
61. National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (November 2013). NICE technology appraisal guidance TA301.
62. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013; 4(6): 151-169.
63. Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, Mitchell P et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye (Lond) 2012; 26(4): 485-493.
64. Ghanchi Fand the Diabetic Retinopathy Guidelines Working Group. The Royal College of Ophthalmologists' clinical guidelines for diabetic retinopathy: a summary. Eye (Lond) 2013; 27: 285-287.
65. Khan S, Wong S, Gorrod R, Gangat I, Hiles S, Dean J et al. Diabetic retinopathy: role of the diabetes specialist eye nurse. J Diabetes Nursing 2010; 14(8): 292-301.
66. The Office of Communications (Ofcom). The Communications Market Report. The Office of Communications 2016.
67. Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR et al. Diabetic Retinopathy Clinical Research Network. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122(2): 375-381.
68. Kannisto KA, Koivunen MH, Välimäki MA. Use of mobile phone text message reminders in health care services: a narrative literature review. J Med Internet Res 2014; 16(10): e222.
69. Gurol-Urganci I, de Jongh T, Vodopivec-Jamsek V, Atun R, Car J. Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database Syst Rev 2013; (12): CD007458, doi:10.1002/14651858.CD007458.pub3.
70. Jutterström L, Hörnsten Å, Sandström H, Stenlund H, Isaksson U. Nurse-led patient-centered self-management support improves HbA1c in patients with type 2 diabetes-A randomized study. Patient Educ Couns 2016; 99(11): 1821-1829.
71. Vyas A, ElKhayat A, Ashwin P. Comparing the glycaemic control of diabetic patients with severe diabetic macular oedema against the NICE guidance-a retrospective audit. ePoster presented at the 16th European Society of Retina Specialists (EURETINA) Congress; Copenhagen, Denmark, September 8-11, 2016.
72. Little P, Stuart B, Hobbs FR, Kelly J, Smith ER, Bradbury KJ et al. An internet-based intervention with brief nurse support to manage obesity in primary care (POWeR+): a pragmatic, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol 2016; 4(10): 821-828.
73. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112(9): 1217-1228.
74. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26(9): 2653-2664.
75. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49(8): 1761-1769.
76. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44(2): 156-163.
77. Cumberland PM, Rahi JS, UK Biobank Eye and Vision Consortium. Visual function, social position, and health and life chances: the UK Biobank Study. JAMA Ophthalmol 2016; 134(9): 959-966.
78. National Academies of Sciences, Engineering, and Medicine. Making Eye Health a Population Health Imperative: Vision for Tomorrow. The National Academies Press: Washington, DC, USA, 2016.
79. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80, 000 people. Diabetes Care 2013; 36(11): 3411-3417.
80. Crawford TN, Alfaro DV 3rd, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009; 5(1): 8-13.
81. Baba A, Zbiba W, Bouayed E, Korbi M, Ghrairi H. Obstructive sleep apnea syndrome. Is it a risk factor for diabetic retinopathy? J Fr Ophtalmol 2016; 39(2): 139-142.
82. Goh JK, Cheung CY, Sim SS, Tan PC, Tan GS, Wong TY. Retinal imaging techniques for diabetic retinopathy screening. J Diabetes Sci Technol 2016; 10(2): 282-294.
83. Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM et al. Diabetic Retinopathy Clinical Research Network. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycaemic control: a randomized clinical trial. JAMA Ophthalmol 2015; 133(8): 888-896.